SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-21-083605
Filing Date
2021-06-21
Accepted
2021-06-21 17:26:02
Documents
12
Period of Report
2021-06-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2120297d1_8ka.htm   iXBRL 8-K/A 30407
  Complete submission text file 0001104659-21-083605.txt   208676

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA casi-20210615.xsd EX-101.SCH 3187
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20210615_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20210615_pre.xml EX-101.PRE 22711
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2120297d1_8ka_htm.xml XML 4180
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-20713 | Film No.: 211032035
SIC: 2836 Biological Products, (No Diagnostic Substances)